Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12274035 | 0.86 | PIK3CD (0.62) | PIK3CDKMT2AMEN1 | |
| SCHEMBL770120 | 0.86 | PSEN1 (0.39) | PIK3CDALPLPIK3CAKMT2AALDH1A1 | |
| SCHEMBL29969209 | 0.85 | PIK3CD (0.44) | CYP3A4CYP2C9CYP2C19PIK3CDALPL | |
| SCHEMBL117014 | 0.76 | ALDH1A1 (0.37) | PIK3CDALPLPIK3CGPIK3CAPIK3CB | |
| SCHEMBL12276604 | 0.75 | PIK3CD (0.41) | PIK3CDALPLPIK3CGPIK3CAPIK3CB | |
| SCHEMBL1650420 | 0.74 | ALDH1A1 (0.43) | PIK3CDALPLKMT2AMEN1ALDH1A1 | |
| SCHEMBL7966932 | 0.73 | PIK3CD (0.42) | CYP3A4CYP2C9CYP2C19PIK3CDALPL | |
| SCHEMBL926027 | 0.72 | PSEN1 (0.52) | PIK3CDPIK3CAKMT2AL3MBTL1NPSR1 | |
| SCHEMBL115597 | 0.72 | PTGS1 (0.36) | ALPLALDH1A1NPSR1 | |
| SCHEMBL1960956 | 0.71 | KMT2A (0.45) | PIK3CDALPLPIK3CGPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422298-B2 | Pyridopyrimidine derivatives and use thereof | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-23 | — | — | US | disclosed |
| US-20150158874-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | CMG PHARMACEUTICAL CO., LTD. | 2015-06-11 | — | — | US | disclosed |
| US-20140113915-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | THE ASAN FOUNDATION (KR) | 2014-04-24 | — | — | US | disclosed |
| US-8664230-B2 | Pyridopyrimidine derivatives and use thereof | THE ASAN FOUNDATION (KR) | 2014-03-04 | — | — | US | disclosed |
| US-20120238587-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-09-20 | — | — | US | disclosed |
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| EP-2311842-A2 | PI3K/M TOR inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-04-20 | — | — | EP | disclosed |
| EP-2303886-A2 | PI3K/M TOR INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010008847-A2 | PI3K/M TOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010008847-A2 | PI3K/M TOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | MTOR, RICTOR, PIK3CA | CYP3A4 1083/4885CYP2C9 549/4885CYP2C19 295/4885 |
| US-20140113915-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | PIK3CA, PIK3CD, PI4KA | CYP3A4 153/4885CYP2C9 267/4885CYP2C19 193/4885 |
| US-20120238587-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | PIK3CA, PIK3CD, PI4KA | CYP3A4 153/4885CYP2C9 267/4885CYP2C19 193/4885 |
| US-20150158874-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | PIK3CA, PIK3CD, PI4KA | CYP3A4 153/4885CYP2C9 267/4885CYP2C19 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.